Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment.

Metastatic colorectal cancer: irinotecan plus infusional, bolus or oral fluoropyrimidines as first-line treatment.

Bibliographic Details
Main Author:	Kerr, D
Format:	Journal article
Language:	English
Published:	2008

Similar Items

Cetuximab plus Irinotecan as third line chemotherapy for metastatic colorectal cancer
by: Moe, M, et al.
Published: (2008)

CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
by: Yuankai Shi, et al.
Published: (2019-05-01)

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan.
by: Midgley, R, et al.
Published: (2007)

Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study
by: Satoru Iwasa, et al.
Published: (2023-04-01)

Results of the use of ramucirumab in combination with irinotecan and fluoropyrimidines in the second-line chemotherapy for disseminated gastric cancer
by: N. S. Besova, et al.
Published: (2019-06-01)

Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer
by: Höhler Thomas, et al.
Published: (2004-07-01)

Predictors of Irinotecan Toxicity and Efficacy in Treatment of Metastatic Colorectal Cancer
by: Adam Paulík, et al.
Published: (2012-01-01)

Triple combination of irinotecan + oxaliplatin + 5-fluorouracil as first-line chemotherapy for metastatic colorectal cancer: first experience with a new treatment regimen
by: A. D. Darenskaya, et al.
Published: (2018-05-01)

Capecitabine/irinotecan combination regimens in colorectal cancer.
by: Kerr, D
Published: (2002)

ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
by: Jesper Andreas Palshof, et al.
Published: (2020-07-01)

Oral Tegafur-Uracil Combination plus Leucovorin versus Other Fluoropyrimidine Agents in Colorectal Cancer: A Systematic Review and Meta-Analysis
by: Satya Pal Kataria, et al.
Published: (2022-01-01)

A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.
by: Sabharwal, A, et al.
Published: (2010)

CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA
by: Taieb, J, et al.
Published: (2012)

Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer
by: Toshiki Masuishi, et al.
Published: (2023-04-01)

EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer
by: Frifeldt Sanne K, et al.
Published: (2011-03-01)

Integration of liposomal irinotecan in the first-line treatment of metastatic pancreatic cancer: try to do not think about the white bear
by: Davide Melisi, et al.
Published: (2024-04-01)

Optimizing the first-line treatment for metastatic colorectal cancer
by: Sara Cherri, et al.
Published: (2023-10-01)

Prognostic Value of Vitamin D Receptor in Patients with Metastatic Colorectal Cancer Received Irinotecan-Based Systemic Treatment as a Second Line
by: Salah Mabrook Khallaf, et al.
Published: (2024-01-01)

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.
by: Rea, D, et al.
Published: (2005)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
by: Akito Fukuda, et al.
Published: (2022-01-01)

Capecitabine/irinotecan in colorectal cancer: European early-phase data and planned trials.
by: Kerr, D
Published: (2002)

Irinotecan in the treatment of colorectal cancer. A literature review
by: V. A. Ivanov, et al.
Published: (2017-04-01)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
by: Madi, A, et al.
Published: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
by: Madi, A, et al.
Published: (2012)

Editorial: Optimizing the first-line treatment for metastatic colorectal cancer
by: Davide Ciardiello, et al.
Published: (2024-01-01)

Fluoropyrimidine Modulation of the Anti-Tumor Immune Response―Prospects for Improved Colorectal Cancer Treatment
by: William H. Gmeiner
Published: (2020-06-01)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
by: Li-Tzong Chen, et al.
Published: (2019-07-01)

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.
by: Folprecht, G, et al.
Published: (2008)

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
by: Adams, R, et al.
Published: (2011)

Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
by: Jiao-Ren Huang, et al.
Published: (2019-02-01)

THE ADDITION OF CETUXIMAB TO OXALIPLATIN-FLUOROPYRIMIDINE CHEMOTHERAPY IN FIRST-LINE ADVANCED COLORECTAL CANCER IN THE MRC COIN TRIAL: IDENTIFICATION OF POTENTIALLY RESPONSIVE SUBSETS OF PATIENTS
by: Maughan, T, et al.
Published: (2010)

Efferent therapy in the first-line drug treatment of metastatic colorectal cancer
by: Z. S. Kotova, et al.
Published: (2018-07-01)

Encorafenib plus cetuximab for the treatment of -mutated metastatic colorectal cancer
by: Javier Ros, et al.
Published: (2022-07-01)

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
by: Letizia Procaccio, et al.
Published: (2023-07-01)

The effective combination therapies with irinotecan for colorectal cancer
by: Yun Chai, et al.
Published: (2024-02-01)

Prognostic value of Bax expression in the primary colon tumor of patients with metastatic colorectal cancer receiving first-line treatment with a triple combination of irinotecan + oxaliplatin + long-term infusion of 5-fluorouracil
by: A. D. Darenskaya, et al.
Published: (2019-06-01)

Circulating miRNA Expression Profiles and Machine Learning Models in Association with Response to Irinotecan-Based Treatment in Metastatic Colorectal Cancer
by: Evangelia Pliakou, et al.
Published: (2022-12-01)

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).
by: Middleton, G, et al.
Published: (2013)

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan and Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)
by: Middleton, G, et al.
Published: (2013)

Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in <i>BRAF<sup>V600E</sup></i>-Mutant Metastatic Colorectal Cancer: The Preliminary Data from a Single-Center Observational Study
by: Hsiang-Lin Tsai, et al.
Published: (2023-12-01)